Stock Comparison

MYO vs PFE

Myomo Inc vs Pfizer Inc

The Verdict

MYO takes this one.

Winner

MYO

Myomo Inc

6.0

out of 10

Solid Pick

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Head-to-Head

$54M

Market Cap

$146.4B

-3.8

P/E Ratio

19.5

-36.7%

Profit Margin

11.8%

-114.9%

Return on Equity

8.4%

1.0

Debt-to-Equity

0.7

Aggressive

Overall Risk

Moderate

6.0

DVR Score

4.0

The Deep Dive

MYO6.0/10

Myomo continues to address a large, underserved neurological rehabilitation market with its MyoPro device, validated by strong regulatory clearances and expanding reimbursement. Q1 2026 results, reported on May 9, 2026, exceeded consensus estimates with $10.1M revenue and narrower EPS loss of ($0.07), building on previous operational improvements. The formalization of Horton Capital's 6.0% stake a...

Full MYO Analysis

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Full PFE Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.